Preclinical study demonstrates that blocking Cx43 attenuates P2X4-mediated neuropathic pain in nerve-injured rats, highlighting Cx43 as a viable therapeutic target.
Neuropathic pain is a growing concern in the medical community, and the search for new analgesic targets for neuropathic pain has become a new hot spot. In this study, we examined whether Cx43 has a key role in neuropathic pain mediated by P2X4 receptor- in rats after peripheral nerve injuring. Our experimental results show that ATP released via Cx43 has a crucial role in P2X4 receptor-mediated neuropathic pain in the rat model of chronic constriction injury (CCI) of the sciatic nerve, and the p38, ERK, and NF-kB signaling pathways have been shown to be involved in the development of neuropathic pain processes. In brief, blockade of CX43 could attenuateP2X4 receptor-mediated neuropathic pain in rats suffering from CCI, and Cx43 may be promising therapeutic targets for the development of novel pharmacological agents in the management of neuropathic pain.
No takes yet. Share an insight, caveat, or question.
Xing et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: